Aduro Biotech, Inc. (NASDAQ:ADRO) – Equities researchers at William Blair cut their FY2017 earnings per share estimates for shares of Aduro Biotech in a report released on Wednesday. William Blair analyst M. Phipps now forecasts that the biotechnology company will earn ($1.24) per share for the year, down from their prior estimate of ($1.22). William Blair has a “Outperform” rating on the stock. William Blair also issued estimates for Aduro Biotech’s Q4 2017 earnings at ($0.32) EPS, Q1 2018 earnings at ($0.36) EPS, Q2 2018 earnings at ($0.39) EPS, Q3 2018 earnings at ($0.43) EPS, Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.61) EPS, FY2019 earnings at ($1.71) EPS, FY2020 earnings at ($1.74) EPS and FY2021 earnings at ($1.52) EPS.

Other equities research analysts also recently issued reports about the stock. BidaskClub downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. HC Wainwright set a $18.00 price target on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Canaccord Genuity set a $30.00 price target on shares of Aduro Biotech and gave the stock a “buy” rating in a report on Thursday, August 3rd. Zacks Investment Research downgraded shares of Aduro Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Finally, Cowen and Company initiated coverage on shares of Aduro Biotech in a report on Tuesday, July 18th. They issued an “outperform” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have assigned a buy rating to the stock. Aduro Biotech currently has an average rating of “Buy” and a consensus price target of $19.14.

TRADEMARK VIOLATION NOTICE: This article was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.watchlistnews.com/fy2017-earnings-estimate-for-aduro-biotech-inc-adro-issued-by-william-blair/1682350.html.

Shares of Aduro Biotech (NASDAQ ADRO) opened at $7.95 on Monday. Aduro Biotech has a twelve month low of $6.01 and a twelve month high of $15.52.

Aduro Biotech (NASDAQ:ADRO) last issued its quarterly earnings results on Tuesday, October 31st. The biotechnology company reported ($0.33) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.03). The firm had revenue of $3.79 million for the quarter, compared to analysts’ expectations of $4.04 million. Aduro Biotech had a negative return on equity of 39.28% and a negative net margin of 548.92%. The business’s quarterly revenue was up .0% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.54) earnings per share.

In other Aduro Biotech news, CEO Stephen T. Isaacs sold 40,000 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $10.78, for a total transaction of $431,200.00. Following the completion of the sale, the chief executive officer now directly owns 213,921 shares in the company, valued at $2,306,068.38. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Jennifer Lew sold 6,600 shares of the business’s stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $10.61, for a total transaction of $70,026.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 260,334 shares of company stock valued at $2,952,556. 6.60% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Legal & General Group Plc grew its stake in Aduro Biotech by 11.2% during the second quarter. Legal & General Group Plc now owns 10,359 shares of the biotechnology company’s stock worth $118,000 after buying an additional 1,043 shares during the period. American International Group Inc. grew its stake in Aduro Biotech by 7.1% during the first quarter. American International Group Inc. now owns 21,840 shares of the biotechnology company’s stock worth $235,000 after buying an additional 1,447 shares during the period. Parametric Portfolio Associates LLC grew its stake in Aduro Biotech by 15.9% during the first quarter. Parametric Portfolio Associates LLC now owns 15,424 shares of the biotechnology company’s stock worth $166,000 after buying an additional 2,119 shares during the period. Voya Investment Management LLC grew its stake in Aduro Biotech by 15.3% during the second quarter. Voya Investment Management LLC now owns 18,935 shares of the biotechnology company’s stock worth $216,000 after buying an additional 2,515 shares during the period. Finally, Nationwide Fund Advisors grew its stake in Aduro Biotech by 12.5% during the second quarter. Nationwide Fund Advisors now owns 23,112 shares of the biotechnology company’s stock worth $263,000 after buying an additional 2,567 shares during the period. Institutional investors own 34.01% of the company’s stock.

About Aduro Biotech

Aduro Biotech, Inc is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company’s product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies.

Earnings History and Estimates for Aduro Biotech (NASDAQ:ADRO)

Receive News & Ratings for Aduro Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro Biotech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.